

**Table I**Overall scores of the efficacy of the quadrivalent vaccine in different populations (\*)

<b>Protocol</b>	<b>Population</b>	<b>Endpoint</b>	<b>Significance (%)</b>
005	MITT 3	CIN 2/3	10.9
005	MITT 3	CIN 3	25.6
015	RMITT-2	CIN 2/3	Efficacy unproven
015	PP	CIN 2/3	Efficacy unproven
007/013/015	PP	CIN 2/3	Efficacy unproven
007/013/015	RPP	CIN 2/3	Efficacy unproven
007/013/015	MITT 3	CIN 2/3	Efficacy unproven
015	RMITT-2	CIN ALL CIN 1 CIN 2/3 CIN 2 CIN 3 AIS	Efficacy unproven Efficacy unproven Efficacy unproven 6.7 Efficacy unproven Efficacy unproven
015	MITT 3	CIN ALL CIN 1 CIN 2/3 CIN 2 CIN 3 AIS	Efficacy unproven Efficacy unproven Efficacy unproven Efficacy unproven Efficacy unproven Efficacy unproven

(\*) VRBPAC. Background Document Gardasil™ HPV Quadrivalent Vaccine May 18, 2006. VRBPAC Meeting.